Sun Guangwei, SiMa Guozhong, Wu Chunhui, Fan Yongzhong, Tan Yong, Wang Zhong, Cheng Gang, Li Jie
Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou Shi, China.
Department of Neurosurgery, Danyang People's Hospital, Danyang Shi, China.
PLoS One. 2018 Jan 19;13(1):e0190515. doi: 10.1371/journal.pone.0190515. eCollection 2018.
The activating mutations of micro RNA (miR)-17 have been revealed in tumors such as human non-Hodgkin's lymphoma and T cell leukemia. However, it is unclear about the role of miR-17 in glioma cells. The current study aimed to investigate effects of miR-17 mimics or inhibitor on the viability and migration of rat glioma C6 cells, and explore possible mechanisms.
The expression of miR-17 in rat glioma C6 cells and normal brain tissue was detected by quantitative PCR. Protein expression of Cyclin D1 in rat glioma C6 cells and normal brain tissue was measured by Western Blot. Glioma C6 cells were transfected with MiR-17 mimics or inhibitor. Cells that were not transfected (Lipofectamine only) and cells that were transfected with nonsense RNA negative control served as control. MTT assay was utilized to detect cell viability, and cell wound scratch assay was utilized to examine the migration index. In addition, protein expression of Cyclin D1, p-Akt and Akt in MiR-17 mimics or inhibitor-transfected glioma C6 cells was detected by Western Blot. This study had been approved by the Medical Ethics Committee of the First Affiliated Hospital of Soochow University. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
The expression of miR-17 was significantly lower, whereas the expression of Cyclin D1 was significantly higher in glioma C6 cells compared to normal brain tissue. MiR-17 mimics decreased the viability and migration of glioma C6 cells markedly at 48 h. In addition, MiR-17 inhibitor increased the viability and migration of glioma C6 cells at 24 and 48 h. The protein expression of Cyclin D1, p-Akt and Akt in glioma C6 cells decreased after transfection with miR-17 mimics for 72 h, and increased after transfection with miR-17 inhibitor for 72 h.
The reduced miR-17 levels in glioma cells increased cell viability and migration, which correlates with increased expression of Cyclin D1, p-Akt and Akt.
微小RNA(miR)-17的激活突变已在人类非霍奇金淋巴瘤和T细胞白血病等肿瘤中被发现。然而,miR-17在胶质瘤细胞中的作用尚不清楚。本研究旨在探讨miR-17模拟物或抑制剂对大鼠胶质瘤C6细胞活力和迁移的影响,并探索其可能的机制。
采用定量PCR检测大鼠胶质瘤C6细胞和正常脑组织中miR-17的表达。通过蛋白质免疫印迹法检测大鼠胶质瘤C6细胞和正常脑组织中细胞周期蛋白D1的蛋白表达。用miR-17模拟物或抑制剂转染胶质瘤C6细胞。未转染的细胞(仅用脂质体转染)和转染无义RNA阴性对照的细胞作为对照。采用MTT法检测细胞活力,细胞划痕试验检测迁移指数。此外,通过蛋白质免疫印迹法检测miR-17模拟物或抑制剂转染的胶质瘤C6细胞中细胞周期蛋白D1、磷酸化Akt和Akt的蛋白表达。本研究已获得苏州大学附属第一医院医学伦理委员会的批准。遵循了所有适用的国际、国家和/或机构关于动物护理和使用的指南。
与正常脑组织相比,胶质瘤C6细胞中miR-17的表达显著降低,而细胞周期蛋白D1的表达显著升高。miR-17模拟物在48小时时显著降低了胶质瘤C6细胞的活力和迁移能力。此外,miR-17抑制剂在24小时和48小时时增加了胶质瘤C6细胞的活力和迁移能力。用miR-17模拟物转染72小时后,胶质瘤C6细胞中细胞周期蛋白D1、磷酸化Akt和Akt的蛋白表达降低,用miR-17抑制剂转染72小时后升高。
胶质瘤细胞中miR-17水平降低会增加细胞活力和迁移能力,这与细胞周期蛋白D1、磷酸化Akt和Akt表达增加有关。